Selective delivery of material to cells
Isolating or identifying a cell based on a physical property of said cell can include providing a cell suspension; passing said suspension through a microfluidic channel that includes a constriction; passing the cell suspension through the constriction; and, contacting said cell suspension solution with a compound. The constriction can be sized to preferentially deform a relatively larger cell compared to a relatively smaller cell.
1. A method for delivering a compound into a cell based on a physical property of said cell comprising:
providing a cell suspension comprising a first group of cells and a second group of cells, wherein the first group of cells comprises tumor cells, and the second group of cells comprises whole blood cells;
passing said cell suspension through and out of a microfluidic channel that includes a constriction, said constriction comprising a width from 4-10 μm, a length of 1-100 μm, and 1-10 constrictions in series, to deliver a compound to the first group of cells to a greater extent than the second group of cells, wherein passage through the constriction disrupts the cell membranes of the first group of cells such that the compound is delivered into the first group of cells to a greater extent than the second group of cells in the cell suspension that passes through and out of the microfluidic channel; and
contacting said cell suspension with the compound.
2. The method of claim 1 , wherein said cell suspension comprises peripheral blood cells.
3. The method of claim 1 , wherein said second group of cells is an erythrocyte-depleted population of peripheral blood cells.
4. The method of claim 1 , wherein said compound has a molecular mass of 0.5 kDa to 5 MDa.
5. The method of claim 1 , wherein said compound has a molecular mass of 3 kDa to 10 kDa.
6. The method of claim 1 , wherein said compound comprises one or more of a detectable marker, an active biomolecule, and a toxin.
7. The method of claim 1 , wherein said compound comprises a detectable marker.
8. The method of claim 1 , wherein second group of cells is whole blood cells are obtained from a subject at risk of or diagnosed as comprising a tumor.
9. The method of claim 8 , wherein said tumor is melanoma, colon, prostate, lung, pancreatic, breast, liver, brain, or blood cancer.
10. The method of claim 1 , wherein the speed of the cells traversing the constriction ranges from 10mm/s to 10m/s.
11. The method of claim 1 , further comprising applying a pressure to the cell suspension to drive the cells suspension through the constriction of the microfluidic channel.
12. The method of claim 1 , wherein said cell suspension comprises the compound or wherein said method further comprises a step of incubating said cell suspension in a solution containing the compound for a predetermined time after it passes through the constriction.
13. The method of claim 12 , wherein the compound comprises a dye, a protein, or a nucleic acid.
14. The method of claim 12 , wherein the compound comprises a magnetic particle, a fluorescent particle, a fluorescent dye, a fluorescent protein, nucleic acid encoding a fluorescent protein, luciferase, or a compound that induces cell death.
15. The method of claim 7 , further comprising sorting the cells in the cell suspension based on uptake of the detectable marker, thereby isolating the first group of cells.
16. The method of claim 7 , further comprising tagging the cells in the cell suspension with an antibody and sorting the cells in the cell suspension based on uptake of the detectable marker and/or antibody tagging, thereby isolating the first group of cells.
17. The method of claim 16 , wherein the antibody binds a target on the first group of cells, and the cells are sorted by presence of the detectable marker and presence of the antibody tag, and wherein the antibody is a blood cell selective antibody.
18. The method of claim 16 , wherein the antibody binds a target on the second group of cells, and cells are sorted by presence of the detectable marker and absence of the antibody tag, and wherein the antibody is a blood cell selective antibody.
19. The method of claim 1 , wherein at least 10% more of the compound is delivered into the first group of calls compared to the second group of cells.